





CORRECTION



Correction: Alpelisib and fulvestrant in *PIK3CA*-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

D. Bello Roufai , A. Gonçalves, T. De La Motte Rouge, S. Akla, C. Blonz, J. Grenier, J. Gligorov, M. Saghatchian, C. Bailleux, H. Simon, I. Desmoulins, Z. Tharin, E. Renaud , M. Bertho, M-A Benderra, S. Delalogue , L. Robert, P. Cottu, J. Y. Pierga, D. Loirat, A. Bertucci, B. Renouf, F. C. Bidard  and F. Lerebours

© The Author(s), under exclusive licence to Springer Nature Limited 2023

Oncogene (2023) 42:1417; <https://doi.org/10.1038/s41388-023-02615-8>

Correction to: *Oncogene* <https://doi.org/10.1038/s41388-022-02585-3>, published online 7 January 2023

In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been '7, 14' and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13.

In the abstract, the word "data" in the second sentence was misspelled "datda"

The original article has been corrected.